GLP-1 Agonists Reduce Bowel Frequency and Esophageal Spasms
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for short bowel syndrome and spastic or hyperactive esophageal motor disorders are not completely effective, leading to ongoing symptoms and complications, with a need for alternative or improved methods to manage these conditions.
Innovation Solution
Administration of a therapeutically effective amount of a GLP-1 receptor agonist, such as exendin or exenatide, to treat short bowel syndrome and spastic or hyperactive esophageal motor disorders, including esophageal spasms, nutcracker esophagus, and achalasia, by reducing bowel movements and esophageal contraction amplitudes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for short bowel syndrome are used, then some symptom relief is achieved, but treatment effectiveness is incomplete and complications persist
Solution Approach 1:
The patent applies parameter changes by introducing a new pharmacological parameter (GLP-1 receptor agonist administration) to fundamentally alter the treatment approach. This changes the biochemical environment in the gastrointestinal tract, stimulating intestinal growth and improving absorptive function, thereby resolving the incomplete effectiveness of current treatments while reducing persistent symptoms and complications
2Area of stationary object
If surgical intervention is performed to lengthen intestine, then absorptive surface area increases, but treatment complexity and risk increase
Solution Approach 1:
The patent replaces the mechanical surgical intervention with a pharmacological approach using GLP-1 receptor agonists. Instead of physically lengthening the intestine through complex surgical procedures, the treatment uses biochemical signaling to stimulate natural intestinal growth and adaptation, thereby achieving increased absorptive surface area while avoiding surgical complexity and associated risks
3Quantity of substance
If parenteral nutrition is used to deliver nutrients, then nutritional delivery is ensured, but treatment dependency increases and quality of life decreases
Solution Approach 1:
The patent applies preliminary action by using GLP-1 receptor agonists to prepare and enhance the intestinal tract's natural absorptive capacity before and during the transition from parenteral to enteral nutrition. This preliminary biochemical optimization enables the intestine to gradually assume nutritional absorption duties, reducing dependency on parenteral nutrition and improving quality of life while maintaining adequate nutrient delivery
Data Source
AI summary
The present invention describes the methods of using incretin mimetics such as GLP-1 receptor agonists, particularly exenatide, to treat short bowel syndrome and spastic or hyperactive esophageal motor disorders.